Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Faherty EA[original query] |
---|
Extragenital gonorrhoea, chlamydia, and HIV co-infection in people with mpox
Herrera K , Lyang J , Holly T , Faherty EA , Luc C , Korban C , Kern D , Tabidze I . Lancet Infect Dis 2023 23 (9) e334-e336 High prevalence of sexually transmitted infections, including gonorrhoea (28%), chlamydia (25%), syphilis (8%), and HIV (38%) co-infections have been reported in the 2022 mpox outbreak,1 which has disproportionately affected men who have sex with men and minoritised racial and ethnic groups.2 Although the outbreak has receded, a modelling analysis predicts that most jurisdictions in the USA could be at risk of resurgence without continued vaccination efforts.3 In previous mpox outbreaks, co-infection with HIV has been associated with poor mpox health outcomes.1, 4 Furthermore, among people with mpox in eight jurisdictions in the USA in 2022, those with HIV co-infection were more likely to report severe symptoms compared with those without HIV co-infection.1 Unprotected anal intercourse confers a significant risk for HIV acquisition as the rectal membrane is susceptible to infection due to its thin and friable nature.5 Previous gonorrhoea and chlamydia diagnoses are also established risk factors for HIV acquisition.6 These findings, along with clinical manifestations of mpox at rectal, genital, and oral sites warrant further investigation. This Correspondence aims to explore predictors, including gonorrhoea and chlamydia sites of infection in the previous 12 months of mpox diagnosis, and HIV co-infection among people with mpox in Chicago, USA. It is hypothesised that a previous or current rectal site of gonorrhoea or chlamydia infection will be associated with an increased prevalence of HIV and mpox co-infection. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure